Sinfatin

Sinfatin is a Spanish biotechnology company specializing in drug repositioning for central nervous system (CNS) disorders. Founded in 2021 and headquartered in Toledo, the company focuses on identifying new therapeutic applications for existing medications to address unmet medical needs, particularly fatigue and motor deficits. Their lead clinical program involves the repurposing of rimonabant, a cannabinoid receptor 1 (CB1) antagonist, for the treatment of symptoms associated with spinal cord injury, stroke, and persistent COVID-19. By utilizing drugs with established safety profiles, Sinfatin aims to accelerate development timelines and provide accessible treatments for neurological conditions. The company's multidisciplinary team combines expertise in medicine, pharmacy, and biology to bridge the gap between scientific research and clinical practice.